- Home
- ICCC vs ATNM Comparison
ICCC vs ATNM Comparison
Compare ICCC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- ATNM
- Stock Information
- Founded
- ICCC 1982
- ATNM 2000
- Country
- ICCC United States
- ATNM United States
- Employees
- ICCC N/A
- ATNM N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- ATNM Health Care
- Exchange
- ICCC Nasdaq
- ATNM Nasdaq
- Market Cap
- ICCC 57.4M
- ATNM 50.2M
- IPO Year
- ICCC 1987
- ATNM N/A
- Fundamental
- Price
- ICCC $6.61
- ATNM N/A
- Analyst Decision
- ICCC
- ATNM Strong Buy
- Analyst Count
- ICCC 0
- ATNM 2
- Target Price
- ICCC N/A
- ATNM $4.50
- AVG Volume (30 Days)
- ICCC 17.1K
- ATNM 108.6K
- Earning Date
- ICCC 11-12-2025
- ATNM 11-13-2025
- Dividend Yield
- ICCC N/A
- ATNM N/A
- EPS Growth
- ICCC N/A
- ATNM N/A
- EPS
- ICCC 0.20
- ATNM N/A
- Revenue
- ICCC $28,274,756.00
- ATNM N/A
- Revenue This Year
- ICCC N/A
- ATNM N/A
- Revenue Next Year
- ICCC N/A
- ATNM N/A
- P/E Ratio
- ICCC $32.15
- ATNM N/A
- Revenue Growth
- ICCC 21.75
- ATNM N/A
- 52 Week Low
- ICCC $3.38
- ATNM $1.03
- 52 Week High
- ICCC $7.60
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- ICCC 58.43
- ATNM 45.01
- Support Level
- ICCC $6.30
- ATNM $1.56
- Resistance Level
- ICCC $6.99
- ATNM $1.64
- Average True Range (ATR)
- ICCC 0.30
- ATNM 0.06
- MACD
- ICCC 0.06
- ATNM -0.00
- Stochastic Oscillator
- ICCC 69.06
- ATNM 23.08
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.